ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

This study is currently recruiting participants.
Verified by Alcon Research, July 2007

Sponsored by: Alcon Research
Information provided by: Alcon Research
ClinicalTrials.gov Identifier: NCT00065728
  Purpose

This is a 24 month study of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.


Condition Intervention Phase
Macular Degeneration
Drug: Anecortave Acetate
Phase III

Genetics Home Reference related topics:   X-linked juvenile retinoschisis   

MedlinePlus related topics:   Macular Degeneration   

ChemIDplus related topics:   Anecortave acetate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:   An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients With Subfoveal Exudative Age-Related Macular Degeneration (AMD)

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Percent of patients who maintain a positive visual acuity outcome and mean change from baseline in logMAR visual acuity score

Estimated Enrollment:   150
Study Start Date:   May 2003

Detailed Description:

Patients will receive posterior juxtascleral injections of 15 mg Anecortave Acetate Sterile Suspension at 6-month intervals during the 24-month study. The patients will receive periodic visual acuity evaluations during the study.

  Eligibility
Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Patients with subfoveal exudative age-related macular degeneration (AMD) who were previously enrolled in long-term studies with anecortave acetate.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065728

Contacts
Contact: Alcon Clinical     817-568-6747     intldev@alconlabs.com    

Locations
United States, Texas
Belgium,France,Germany,Hungary,Italy,Netherlands,Poland,Spain,Sweden,UK     Recruiting
      Central Contact Ft. Worth, Texas, United States, 76134

Sponsors and Collaborators
Alcon Research

Investigators
Study Director:     Terry Wiernas, PhD     Alcon Research    
  More Information

Click here for more information about this study: A Phase III Clinical Trial for AMD: Information for Potential Participants  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   C-03-15
First Received:   July 31, 2003
Last Updated:   July 13, 2007
ClinicalTrials.gov Identifier:   NCT00065728
Health Authority:   United States: Food and Drug Administration

Keywords provided by Alcon Research:
AMD  
age-related macular degeneration  
Anecortave  
Acetate  
Wet form of age-related macular degeneration
CNV
Anecortave Acetate

Study placed in the following topic categories:
Eye Diseases
Retinal Degeneration
Macular Degeneration
Retinal Diseases
Retinal degeneration

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers